(Q24245407)

29 October 2023

NP Adams

1

N P

Adams

1 reference

29 October 2023

TJ Lasserson

series ordinal

3

author given names

T J

author last names

Lasserson

1 reference

29 October 2023

PW Jones

series ordinal

4

author given names

P W

author last names

Jones

1 reference

29 October 2023

CJ Cates

series ordinal

5

author given names

C

author last names

Cates

1 reference

Cochrane Database of Systematic Reviews

29 October 2023

language of work or name

1 reference

19 October 2005

0 references

published in

0 references

cites work

The effect of fluticasone propionate on functional status and sleep in children with asthma and on the quality of life of their parents

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Children with mild asthma: do they benefit from inhaled corticosteroids?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Efficacy and safety of fluticasone propionate 250 microg administered once daily in patients with persistent asthma treated with or without inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Fluticasone propionate induced alterations to lung function and the immunopathology of asthma over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Fluticasone propionate compared with theophylline for mild-to-moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Fifty μg b.i.d. of inhaled fluticasone propionate (FP) are effective in stable asthmatics previously treated with a higher dose of FP

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Fluticasone propionate in children with moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Potential effects of fluticasone propionate on bone mineral density in patients with asthma: a 2-year randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Fluticasone propionate via the Diskhaler or hydrofluoroalkane-134a metered-dose inhaler on methacholine-induced airway hyperresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

The effect of low-dose inhaled fluticasone propionate on exhaled nitric oxide in asthmatic patients and comparison with oral zafirlukast

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: a randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromogl

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Fluticasone propionate results in improved glucocorticoid receptor binding affinity and reduced oral glucocorticoid requirements in severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Fluticasone propionate improves quality of life in patients with asthma requiring oral corticosteroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Impact of fluticasone propionate powder on health-related quality of life in patients with moderate asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Achieving guideline-based asthma control: does the patient benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Improved ability to perform strenuous activities after treatment with fluticasone propionate/salmeterol combination in patients with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Effect of inhaled fluticasone on bronchial responsiveness to neurokinin A in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Effects of 2 inhaled corticosteroids on growth: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Randomized controlled trial of fluticasone in preschool children with intermittent wheeze

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Efficacy and safety of inhaled corticosteroids. New developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Fluticasone given once versus twice a day: meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

A comparison of the efficacy and safety of inhaled corticosteroids in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Establishing a therapeutic index for the inhaled corticosteroids: part II. Comparisons of systemic activity and safety among different inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

The Effect of Inhaled Fluticasone Propionate in the Treatment of Young Asthmatic Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

A placebo controlled trial of fluticasone propionate in asthmatic children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Adrenocortical activity with repeated administration of one-daily inhaled fluticasone propionate and budesonide in asthmatic adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Growth in asthmatic children treated with fluticasone propionate. Fluticasone Propionate Asthma Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Patient satisfaction with the Diskhaler and the Diskus inhaler, a new multidose power delivery system for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Fluticasone propionate 50 micrograms BID versus 100 micrograms BID in the treatment of children with persistent asthma. Fluticasone Propionate Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Effects of inhaled steroids on methacholine-induced bronchoconstriction and gas trapping in mild asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Inhaled corticosteroid therapy reduces the early morning peak in cortisol and aldosterone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Protective effects of fluticasone on allergen-induced airway responses and sputum inflammatory markers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Dose-response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Effects of inhaled corticosteroid therapy on expression and DNA-binding activity of nuclear factor kappaB in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Reduced airway distensibility, fixed airflow limitation, and airway wall remodeling in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Effect of inhaled fluticasone propionate on airway responsiveness in treatment-naive individuals--a lesser benefit in females

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Effects of fluticasone propionate on methacholine dose-response curves in nonsmoking atopic asthmatics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in patients with mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Compliance during long-term treatment with fluticasone propionate in subjects with early signs of asthma or chronic obstructive pulmonary disease (COPD): results of the Detection, Intervention, and Monitoring Program of COPD and Asthma (DIMCA) Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

Importance of selected inhaler characteristics and acceptance of a new breath-actuated powder inhalation device

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003135.PUB3

7 January 2021

10.1002/14651858.CD003135.PUB3

Identifiers

DOI

0 references

Fatcat ID

release_426uqs53wjc6bbe7st4ukesn6m

0 references